glp-1 and nad EllieMD Science's 2023 Breakthrough: GLP-1R Agonists

A provider-guided tirzepatide microdosing program designed to support metabolic health, cardiovascular risk reduction, and sustainable weight managementenhanced with glycine for optimized performance and recovery.

These medications often reduce appetite, making it important to focus on nutrient-dense, high-protein meals that support satiety and muscle maintenance

Could addiction be next?

Free Consultation 24/7 with The Lidji Firm attorney.

Includes MHRA Yellow Card reporting guidance.

When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations